Figures on vaccination

  • Vaccines 716.3 million doses delivered
  • Vaccines 72.7 %of the EU adult population fully vaccinated

Last updated: 16 September 2021. Source: Vaccines producers and ECDC data.

Highlights

Information about vaccination in the EU

 

 

Securing doses of future vaccines

The European Commission has been negotiating intensely to build a diversified portfolio of vaccines for EU citizens at fair prices. Contracts have been concluded with 7 promising vaccine developers, securing a portfolio of up to 4.6 billion doses.

Deliveries of vaccine doses to European Union countries have increased steadily since December. Vaccination gathers pace across the European Union.

The Commission has so far given 4 conditional marketing authorisations for the vaccines developed by BioNTech and Pfizer, Moderna, AstraZeneca and Janssen Pharmaceutica NV following EMA positive assessment of their safety and efficacy. Several other vaccines are at different stages of assessment by the European Medicines Agency (EMA).

The Commission is working closely with the industry to step up vaccine manufacturing capacity in the EU.

At the same time, the Commission has started work to anticipate and tackle new variants of the virus and to rapidly develop and produce on a large-scale vaccines effective against those variants.

This is why the European Commission has launched the HERA Incubator. It will bring together science, industry and public authorities, to speed up work and leverage all available resources to enable Europe to respond to this threat.

 

  • up to 4.6 billion doses

Company

Type of vaccine

Number of doses

(needed per person)

Number of doses

(secured)

Status
BioNTech and Pfizer mRNA 2 doses 2.4 billion* Approved
Moderna mRNA 2 doses 460 million Approved
CureVac mRNA 2 doses 405 million Under EMA rolling review
AstraZeneca adenovirus 2 doses 400 million Approved
Johnson & Johnson/Janssen Pharmaceuticals adenovirus 1 dose 400 million Approved
Sanofi-GSK protein 2 doses 300 million Under EMA rolling review
Novavax protein 2 doses 200 million** Under EMA rolling review

*option to purchase 900 million doses, **option to purchase 100 million doses

The Commission has also concluded exploratory talks with

  • Valneva with a view to purchase up to 60 million doses.

Safety reports

The European Medicines Agency publishes safety updates for the COVID-19 vaccines authorised in the EU. EMA releases a monthly update for each authorised COVID-19 vaccine.

The safety updates summarise the data that have become available since the vaccine's authorisation. They also indicate whether any safety information requires further investigation.

For more information, visit the EMA webpage.

Check the facts

Disinformation on the coronavirus is thriving. It is important that you get updated information from authoritative sources only. We suggest that you follow the advice of your public health authorities, and the websites of relevant EU and international organisations: the European Centre for Disease Control (ECDC ) and the World Health Organisation (WHO).

You can also help by not sharing unverified information that comes from dubious sources.

Fighting disinformation

The EU vaccine strategy

With the EU Vaccines Strategy, the EU is supporting efforts to accelerate the development and availability of safe and effective vaccines in a timeframe between 12 and 18 months, if not earlier. Delivering on this complex task requires running clinical trials in parallel with investing in production capacity to be able to produce millions, or even billions, of doses of a successful vaccine.

Videos

Interview about vaccination with Ms Marie-Francoise Fuchs

Interview about vaccination with Ms Marie-Francoise Fuchs

How vaccines work

How do vaccines work?

 

More videos and images about COVID-19 vaccines

Documents